FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126642361> ?p ?o ?g. }

• W3126642361 endingPage "4838" @default.
• W3126642361 startingPage "4829" @default.
• W3126642361 abstract "This study aimed to analyze timing and sites of recurrence for patients receiving neoadjuvant chemotherapy for gastric cancer. Neoadjuvant chemotherapy followed by surgical resection is the standard treatment for locally advanced gastric cancer in the West, but limited information exists as to timing and patterns of recurrence in this setting.Patients with clinical stage 2 or 3 gastric cancer treated with neoadjuvant chemotherapy followed by curative-intent resection between January 2000 and December 2015 were analyzed for 5-year recurrence-free survival (RFS) as well as timing and site of recurrence.Among 312 identified patients, 121 (38.8%) experienced recurrence during a median follow-up period of 46 months. The overall 5-year RFS rate was 58.9%, with RFS rates of 95.8% for ypT0N0, 81% for ypStage 1, 77.4% for ypStage 2, and 22.9% for ypStage 3. The first site of recurrence was peritoneal for 49.6%, distant (not peritoneal) for 45.5%, and locoregional for 11.6% of the patients. The majority of the recurrences (84.3%) occurred within 2 years. Multivariate analysis showed that ypT4 status was an independent predictor for recurrence within 1 year after surgery (odds ratio, 2.58; 95% confidence interval, 1.10-6.08; p = 0.030).The majority of the recurrences for patients with clinical stage 2 or 3 gastric cancer who received neoadjuvant chemotherapy and underwent curative resection occurred within 2 years. After neoadjuvant chemotherapy, pathologic T stage was a useful risk predictor for early recurrence." @default.
• W3126642361 created "2021-02-15" @default.
• W3126642361 creator A5007737951 @default.
• W3126642361 creator A5019892202 @default.
• W3126642361 creator A5021215219 @default.
• W3126642361 creator A5021407180 @default.
• W3126642361 creator A5027745721 @default.
• W3126642361 creator A5035865205 @default.
• W3126642361 creator A5037658285 @default.
• W3126642361 creator A5051277222 @default.
• W3126642361 creator A5053992102 @default.
• W3126642361 creator A5068026508 @default.
• W3126642361 creator A5069991204 @default.
• W3126642361 creator A5075518419 @default.
• W3126642361 date "2021-02-10" @default.
• W3126642361 modified "2023-10-05" @default.
• W3126642361 title "Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of Recurrence" @default.
• W3126642361 cites W1967835489 @default.
• W3126642361 cites W1976455522 @default.
• W3126642361 cites W1983001359 @default.
• W3126642361 cites W1988543553 @default.
• W3126642361 cites W1991074169 @default.
• W3126642361 cites W2005958581 @default.
• W3126642361 cites W2009190689 @default.
• W3126642361 cites W2009441994 @default.
• W3126642361 cites W2034949681 @default.
• W3126642361 cites W2105423180 @default.
• W3126642361 cites W2115072149 @default.
• W3126642361 cites W2116893774 @default.
• W3126642361 cites W2129787938 @default.
• W3126642361 cites W2144190066 @default.
• W3126642361 cites W2148307803 @default.
• W3126642361 cites W2166617017 @default.
• W3126642361 cites W2380453891 @default.
• W3126642361 cites W2429135718 @default.
• W3126642361 cites W2536596501 @default.
• W3126642361 cites W2559995252 @default.
• W3126642361 cites W2573152477 @default.
• W3126642361 cites W2598651660 @default.
• W3126642361 cites W2616174877 @default.
• W3126642361 cites W2791071232 @default.
• W3126642361 cites W2798252125 @default.
• W3126642361 cites W2930930235 @default.
• W3126642361 cites W2938774982 @default.
• W3126642361 cites W4242151806 @default.
• W3126642361 cites W57848150 @default.
• W3126642361 doi "https://doi.org/10.1245/s10434-021-09624-5" @default.
• W3126642361 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33566242" @default.
• W3126642361 hasPublicationYear "2021" @default.
• W3126642361 type Work @default.
• W3126642361 sameAs 3126642361 @default.
• W3126642361 citedByCount "12" @default.
• W3126642361 countsByYear W31266423612022 @default.
• W3126642361 countsByYear W31266423612023 @default.
• W3126642361 crossrefType "journal-article" @default.
• W3126642361 hasAuthorship W3126642361A5007737951 @default.
• W3126642361 hasAuthorship W3126642361A5019892202 @default.
• W3126642361 hasAuthorship W3126642361A5021215219 @default.
• W3126642361 hasAuthorship W3126642361A5021407180 @default.
• W3126642361 hasAuthorship W3126642361A5027745721 @default.
• W3126642361 hasAuthorship W3126642361A5035865205 @default.
• W3126642361 hasAuthorship W3126642361A5037658285 @default.
• W3126642361 hasAuthorship W3126642361A5051277222 @default.
• W3126642361 hasAuthorship W3126642361A5053992102 @default.
• W3126642361 hasAuthorship W3126642361A5068026508 @default.
• W3126642361 hasAuthorship W3126642361A5069991204 @default.
• W3126642361 hasAuthorship W3126642361A5075518419 @default.
• W3126642361 hasBestOaLocation W31266423612 @default.
• W3126642361 hasConcept C121608353 @default.
• W3126642361 hasConcept C126322002 @default.
• W3126642361 hasConcept C141071460 @default.
• W3126642361 hasConcept C143998085 @default.
• W3126642361 hasConcept C146357865 @default.
• W3126642361 hasConcept C151730666 @default.
• W3126642361 hasConcept C156957248 @default.
• W3126642361 hasConcept C2776694085 @default.
• W3126642361 hasConcept C2778292576 @default.
• W3126642361 hasConcept C2780140570 @default.
• W3126642361 hasConcept C38180746 @default.
• W3126642361 hasConcept C44249647 @default.
• W3126642361 hasConcept C530470458 @default.
• W3126642361 hasConcept C71924100 @default.
• W3126642361 hasConcept C86803240 @default.
• W3126642361 hasConceptScore W3126642361C121608353 @default.
• W3126642361 hasConceptScore W3126642361C126322002 @default.
• W3126642361 hasConceptScore W3126642361C141071460 @default.
• W3126642361 hasConceptScore W3126642361C143998085 @default.
• W3126642361 hasConceptScore W3126642361C146357865 @default.
• W3126642361 hasConceptScore W3126642361C151730666 @default.
• W3126642361 hasConceptScore W3126642361C156957248 @default.
• W3126642361 hasConceptScore W3126642361C2776694085 @default.
• W3126642361 hasConceptScore W3126642361C2778292576 @default.
• W3126642361 hasConceptScore W3126642361C2780140570 @default.
• W3126642361 hasConceptScore W3126642361C38180746 @default.
• W3126642361 hasConceptScore W3126642361C44249647 @default.
• W3126642361 hasConceptScore W3126642361C530470458 @default.
• W3126642361 hasConceptScore W3126642361C71924100 @default.
• W3126642361 hasConceptScore W3126642361C86803240 @default.

• next